EC
CGEM icon

EcoR1 Capital’s Cullinan Oncology CGEM Stock Holding History

EcoR1 Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-246,410
Closed -$2.52M – 58
2023
Q1 		$2.52M Sell
246,410
-788,628
-76% -$8.69M 0.08% 42
2022
Q4 		$10.9M Sell
1,035,038
-108,180
-9% -$1.31M 0.33% 37
2022
Q3 		$14.7M Sell
1,143,218
-26,671
-2% -$359K 0.43% 31
2022
Q2 		$15M Buy
+1,169,889
New +$13.3M 0.52% 34

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EcoR1 Capital's CGEM Position: Q2 2023 in Review

EcoR1 Capital sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 246,410 shares — an estimated $2.52M sold.

EcoR1 Capital first reported a position in CGEM in Q2 2022 and held it in 4 quarters. The position peaked at $15M in Q2 2022. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

  • EcoR1 Capital reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
  • EcoR1 Capital sold 246,410 Cullinan Oncology shares in Q2 2023, an estimated $2.52M.
  • EcoR1 Capital first reported a position in Cullinan Oncology in Q2 2022 and held it in 4 quarters.
  • EcoR1 Capital's Cullinan Oncology position peaked at $15M in Q2 2022.
  • 106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.